SEQ-9

• Description :

  SEQ-9 is an orally active Mycobacterium tuberculosis (Mtb) 23S bacterial ribosome inhibitor with an IC50 of approximately 170 nM for unmethylated Mtb ribosomes. SEQ-9 also potently inhibits A2296 methylated ribosomes. SEQ-9 can be used to study bacterial infection and drug resistance[1].

• UNSPSC :

  12352005

• Target :

  Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/seq-9.html

• Solubility :

  10 mM in DMSO

• Smiles :

  C[C@H]([C@@]([C@@H]1C)([H])OC([C@H](C)[C@H]([C@@H]([C@H]([C@@H](C)C[C@@](OC(NC(C)(C)CNS(C2=CC=CC=C2)(=O)=O)=O)(C)C([C@@H]([C@@H]1OC(CC(C)C)=O)C)=O)O[C@]3([H])O[C@]([H])(C)C/C([C@H]3O)=N/OC)C)O[C@]4([H])O[C@@H](C)CN(C)[C@H](C)C4)=O)O[C@@]5([H])[C@H](OC)[C@H](OC)[C@H](O)[C@](C)([H])O5

• Molecular Formula :

  C60H100N4O20S

• Molecular Weight :

  1229.52

• References & Citations :

  [1]ZHICHENG CUI. Structural Studies of Mycobacterium Tuberculosis Ribosome: From Translational Regulation to Drug Resistance. Texas A&M University. 2021 Apr 12.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported